<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Evotec Se — News on 6ix</title>
<link>https://6ix.com/company/evotec-se</link>
<description>Latest news and press releases for Evotec Se on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 08 Jan 2026 06:50:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/evotec-se" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836034578dffbe2df13502e.webp</url>
<title>Evotec Se</title>
<link>https://6ix.com/company/evotec-se</link>
</image>
<item>
<title>Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access</title>
<link>https://6ix.com/company/evotec-se/news/just-evotec-biologics-receives-grant-for-ai-driven-optimization-of-monoclonal-antibody-developability-for-affordable-access</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/just-evotec-biologics-receives-grant-for-ai-driven-optimization-of-monoclonal-antibody-developability-for-affordable-access</guid>
<pubDate>Thu, 08 Jan 2026 06:50:00 GMT</pubDate>
<description>Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, ...</description>
</item>
<item>
<title>Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations</title>
<link>https://6ix.com/company/evotec-se/news/evotec-appoints-dr-sarah-fakih-as-evp-head-of-global-communications-and-investor-relations</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-appoints-dr-sarah-fakih-as-evp-head-of-global-communications-and-investor-relations</guid>
<pubDate>Fri, 02 Jan 2026 05:30:00 GMT</pubDate>
<description>Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment HAMBURG, DE / ACCESS Newswire / January 2, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime ...</description>
</item>
<item>
<title>Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz</title>
<link>https://6ix.com/company/evotec-se/news/evotec-closes-sale-of-just-evotec-biologics-toulouse-site-to-sandoz</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-closes-sale-of-just-evotec-biologics-toulouse-site-to-sandoz</guid>
<pubDate>Mon, 08 Dec 2025 06:20:00 GMT</pubDate>
<description>All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse ...</description>
</item>
<item>
<title>Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome</title>
<link>https://6ix.com/company/evotec-se/news/evotec-partner-bayer-starts-phase-2-study-for-treatment-of-patients-with-alport-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-partner-bayer-starts-phase-2-study-for-treatment-of-patients-with-alport-syndrome</guid>
<pubDate>Thu, 04 Dec 2025 07:50:00 GMT</pubDate>
<description>Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome Milestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBURG, DE / ACCESS Newswire / December 4, 2025 / Evotec ...</description>
</item>
<item>
<title>Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership</title>
<link>https://6ix.com/company/evotec-se/news/evotec-receives-milestone-payment-from-bristol-myers-squibb-following-ind-acceptance-in-strategic-protein-degradation-partnership</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-receives-milestone-payment-from-bristol-myers-squibb-following-ind-acceptance-in-strategic-protein-degradation-partnership</guid>
<pubDate>Wed, 12 Nov 2025 07:00:00 GMT</pubDate>
<description>Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November ...</description>
</item>
<item>
<title>Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-reports-9m-2025-results-continued-strong-execution-on-strategic-priorities</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-reports-9m-2025-results-continued-strong-execution-on-strategic-priorities</guid>
<pubDate>Wed, 05 Nov 2025 07:00:00 GMT</pubDate>
<description>Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business ...</description>
</item>
<item>
<title>In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties</title>
<link>https://6ix.com/company/evotec-se/news/in-a-landmark-industry-transaction-evotec-signs-agreement-with-sandoz-resulting-in-payments-potentially-over-us-dollar650-m-plus-royalties</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/in-a-landmark-industry-transaction-evotec-signs-agreement-with-sandoz-resulting-in-payments-potentially-over-us-dollar650-m-plus-royalties</guid>
<pubDate>Tue, 04 Nov 2025 21:30:00 GMT</pubDate>
<description>Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strategy through better monetization of technology and ...</description>
</item>
<item>
<title>Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-to-announce-results-for-the-first-nine-months-2025-on-05-november-2025</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-to-announce-results-for-the-first-nine-months-2025-on-05-november-2025</guid>
<pubDate>Wed, 29 Oct 2025 09:10:00 GMT</pubDate>
<description>HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, ...</description>
</item>
<item>
<title>Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb</title>
<link>https://6ix.com/company/evotec-se/news/evotec-announces-progress-in-preclinical-neuroscience-partnership-with-bristol-myers-squibb</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-announces-progress-in-preclinical-neuroscience-partnership-with-bristol-myers-squibb</guid>
<pubDate>Mon, 27 Oct 2025 06:50:00 GMT</pubDate>
<description>Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: ...</description>
</item>
<item>
<title>Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-reports-h1-2025-results-strong-progress-on-strategy-execution</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-reports-h1-2025-results-strong-progress-on-strategy-execution</guid>
<pubDate>Wed, 13 Aug 2025 05:25:00 GMT</pubDate>
<description>Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect ...</description>
</item>
<item>
<title>Evotec SE to announce first half-year results 2025 on 13 August 2025</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-to-announce-first-half-year-results-2025-on-13-august-2025</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-to-announce-first-half-year-results-2025-on-13-august-2025</guid>
<pubDate>Wed, 06 Aug 2025 08:15:00 GMT</pubDate>
<description>HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, ...</description>
</item>
<item>
<title>Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-and-sandoz-ag-planning-potential-sale-of-just-evotec-biologics-toulouse-site</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-and-sandoz-ag-planning-potential-sale-of-just-evotec-biologics-toulouse-site</guid>
<pubDate>Wed, 30 Jul 2025 05:45:00 GMT</pubDate>
<description>HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) ...</description>
</item>
<item>
<title>Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site</title>
<link>https://6ix.com/company/evotec-se/news/evotec-and-sandoz-evolve-their-strategic-partnership-and-agree-on-potential-sale-of-just-evotec-biologics-toulouse-site</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-and-sandoz-evolve-their-strategic-partnership-and-agree-on-potential-sale-of-just-evotec-biologics-toulouse-site</guid>
<pubDate>Wed, 30 Jul 2025 05:40:00 GMT</pubDate>
<description>Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar ...</description>
</item>
<item>
<title>Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix</title>
<link>https://6ix.com/company/evotec-se/news/evotec-adjusts-revenue-guidance-and-confirms-profit-guidance-anticipating-a-more-profitable-revenue-mix</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-adjusts-revenue-guidance-and-confirms-profit-guidance-anticipating-a-more-profitable-revenue-mix</guid>
<pubDate>Mon, 21 Jul 2025 10:10:00 GMT</pubDate>
<description>Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms High-margin technology license revenues expected to have a stronger impactthan anticipated ...</description>
</item>
<item>
<title>Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-adjusts-revenue-guidance-while-confirming-profit-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-adjusts-revenue-guidance-while-confirming-profit-guidance</guid>
<pubDate>Mon, 21 Jul 2025 09:50:00 GMT</pubDate>
<description>HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance ...</description>
</item>
<item>
<title>Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury</title>
<link>https://6ix.com/company/evotec-se/news/evotec-joins-nurture-aki-consortium-to-gain-multi-omics-based-molecular-understanding-of-acute-kidney-injury</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-joins-nurture-aki-consortium-to-gain-multi-omics-based-molecular-understanding-of-acute-kidney-injury</guid>
<pubDate>Wed, 25 Jun 2025 05:50:00 GMT</pubDate>
<description>NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK The study focuses on ...</description>
</item>
<item>
<title>Evotec SE: Results of the Annual General Meeting 2025</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-results-of-the-annual-general-meeting-2025</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-results-of-the-annual-general-meeting-2025</guid>
<pubDate>Tue, 03 Jun 2025 21:28:27 GMT</pubDate>
<description>All agenda items adopted Under the topic "Pioneering Drug Discovery" CEO Dr Christian Wojczewski presented Evotec's current situation and strategic outlook 46.45% of the registered share capital represented HAMBURG, Germany - June 3, 2025 (NEWM...</description>
</item>
<item>
<title>Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments</title>
<link>https://6ix.com/company/evotec-se/news/evotec-receives-dollar-25-m-grant-to-generate-next-generation-tuberculosis-treatments</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-receives-dollar-25-m-grant-to-generate-next-generation-tuberculosis-treatments</guid>
<pubDate>Wed, 07 May 2025 05:50:00 GMT</pubDate>
<description>Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partnership on evaluating new treatment regimens aimed ...</description>
</item>
<item>
<title>Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-reports-q1-2025-results-paving-the-way-for-2025-growth-in-soft-market-environment</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-reports-q1-2025-results-paving-the-way-for-2025-growth-in-soft-market-environment</guid>
<pubDate>Tue, 06 May 2025 05:20:00 GMT</pubDate>
<description>Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation partnership with Bristol Myers Squibb Strategy ...</description>
</item>
<item>
<title>Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025</title>
<link>https://6ix.com/company/evotec-se/news/evotec-se-to-announce-results-for-the-first-quarter-2025-on-6-may-2025</link>
<guid isPermaLink="true">https://6ix.com/company/evotec-se/news/evotec-se-to-announce-results-for-the-first-quarter-2025-on-6-may-2025</guid>
<pubDate>Tue, 29 Apr 2025 08:30:00 GMT</pubDate>
<description>HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025. The Company is going ...</description>
</item>
</channel>
</rss>